Mitochondrial DNA and TLR9 in Pulmonary Fibrosis

肺纤维化中的线粒体 DNA 和 TLR9

• 批准号: 10226817
• 负责人: Changwan Ryu
• 金额: $ 16.79万
• 依托单位: YALE UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2020
• 资助国家: 美国
• 起止时间: 2020-08-01 至 2025-07-31
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10226817
• 关键词: Activities of Daily Living; Adult; Area; Biological Assay; Biomedical Engineering; Biometry; Bleomycin; Bronchoalveolar Lavage; Cells; Cellular Assay; Chronic lung disease; Clinical; Collagen; Computational Biology; Department chair; Deposition; Development; Disease; Dose; Environment; Experimental Models; Exposure to; Extracellular Matrix; Fellowship; Fibroblasts; Fibrosis; Funding; Genes; Genomics; Goals; Grant; Harvest; Human; Immune system; Immunologic Receptors; In Vitro; Inflammation; Inflammatory; Inhalation; Interstitial Lung Diseases; Laboratories; Lead; Longitudinal cohort; Lung; Lung Transplantation; Lung diseases; Measurement; Mediating; Mentors; Mentorship; Methods; Mitochondria; Mitochondrial DNA; Modeling; Molecular; Mus; Myofibroblast; Natural Immunity; Nature; Outcome; Pathogenesis; Patients; Pattern; Pharmaceutical Preparations; Phenocopy; Phenotype; Physicians; Plasma; Play; Process; Pulmonary Fibrosis; Radiation; Reporter; Research; Research Personnel; Research Project Grants; Role; Scientist; Secondary to; Smooth Muscle Actin Staining Method; Structure of parenchyma of lung; TGFB1 gene; TLR9 gene; Testing; Time; Toxic Environmental Substances; Training; Transforming Growth Factor-Beta Overexpression; Work; alveolar epithelium; base; career; career development; cell injury; cohort; combat; cost; curative treatments; drug development; epithelial injury; extracellular; idiopathic pulmonary fibrosis; immune activation; in vitro Model; in vivo; inhibitor/antagonist; insight; mechanotransduction; metabolic profile; mortality; novel; novel therapeutics; overexpression; polyacrylamide hydrogels; response; response to injury; side effect; single-cell RNA sequencing; translational medicine; translational study

PROJECT SUMMARY Candidate: My long-term career goal is to develop a successful academic career and become an independently funded physician-scientist focused on the study of innate immunity in idiopathic pulmonary fibrosis (IPF). Under the guidance of my mentor and research advisors, I have received training in laboratory-based assays, in vitro models of IPF, translational medicine, and biostatistics. I have proposed career development activities that will allow me to continue this training, but also develop unique expertise that is distinct from my mentor in the areas of (1) innate immunity and (2) computational biology. Mentors and Environment: I will be mentored by Dr. Erica Herzog, a globally renowned IPF investigator who has studied the immunopathogensis of fibrosis with an extremely impressive track record of successful mentees. My advisors include Dr. Naftali Kaminski, a well-known IPF investigator whose visionary methods in the genomic profiling of fibrotic lung disease have revolutionized the field; Dr. Wajahat Mehal, who has been lauded for his work with mitochondrial DNA (mtDNA) and Toll-Like Receptor 9 (TLR9) in the development of fibrosis; Dr. Min-Jong Kang, an expert in mitochondrial innate immunity in chronic lung disease; and Dr. Anjelica Gonzalez, who has developed novel methods in bioengineering for ex vivo modeling of the fibrotic microenvironment. My department Chair (Dr. Gary Desir) has assured me that at least 75% of my time will be dedicated to my career development, and he and my Section Chief (Dr. Kaminski) have detailed their commitment. Mentored Research Project: The pathogenesis of IPF involves the uncontrolled accumulation of activated myofibroblasts, which arise in response to TGFβ1 mediated interactions with the stiff fibrotic lung microenvironment. The innate immune receptor TLR9, which recognizes and responds to mtDNA derived from injured cells, has been shown to have a significant role in mediating this process. We showed that mtDNA is released by TGFβ1-stimulated and stiffness-induced normal human lung fibroblasts, where it induces myofibroblast transformation in a manner that phenocopies fibroblasts harvested from the IPF lung. In the clinical setting, mtDNA concentrations are elevated in the plasma of IPF subjects, where it displays a robust association with all-cause mortality in two independent cohorts. Our subsequent studies reveal that mice deficient in TLR9 are protected from fibrosis caused by lung specific overexpression of the bioactive form of the human TGFβ1 gene and by repetitive administration of low-dose inhaled bleomycin. While exciting, however, these studies are limited by not having determined whether mtDNA-induced fibroblast activation requires TLR9, whether TLR9’s fibrosis promoting effects are mediated through fibroblasts in vivo, and the nature of the mtDNA-TLR9 relationship in IPF. Because elucidation of these questions might substantially impact our understanding of pulmonary fibrosis, this K08 application proposes a state-of-the-art set of translational studies to test the hypothesis that mtDNA-TLR9 interaction drives fibroblast activation and fibrosis in the adult lung.

项目总结